PATHOGENETIC ASPECTS OF THE OBSTETRIC COMPLICATIONS᾽ FORMATION IN PREGNANT WOMEN WITH NONALCOHOLIC FATTY LIVER DISEASE IN OVERWEIGHT (LITERATURE REVIEW)
DOI:
https://doi.org/10.11603/24116-4944.2020.2.11835Keywords:
functional state of the liverAbstract
Among the pathological conditions that are factors threatening the course of pregnancy, a special place is occupied by disorders of lipid metabolism. According to the WHO, 90 % of overweight women develop early manifestations of hepatic steatosis at the age of 20–25, which leads to non-alcoholic steatohepatitis over the next five years of life. Therefore, overweight women are at risk for the development of obstetric and perinatal complications, in the genesis of which a significant role is given to metabolic disorders in the liver.
The aim of the study – to analyze the current literature on lipid profile, endothelial function, biochemical markers, the role of the liver in the regulation of lipid metabolism and key risk factors for steatosis at a young age that may worsen pregnancy and childbirth in pregnant women with nonalcoholic fatty liver disease (NAFLD) and obesity and determine the optimal methods of diagnostics, prevention and treatment of obstetric and perinatal complications in overweight pregnant women with NAFLD.
Conclusion. The combination of NAFLD and obesity has a significant impact on the development of obstetric and perinatal complications.
References
Bredman, S.L., Neuschwander-Tetri, B.A., Rinella, M., & Sanyal, A.J. (2018). Mechanisms of NAFLD development and therapeutic strategies. Nat. Med., 24 (7), 908-922. DOI: 10.1038/s41591-018-0104-9.
Kedyk, A.V., & Zhulkevych, I.V. (2019). State of lipid and fat-acidic spectrum of blood plasma in the residents of the plain regions of transcarpathia depending on age and trophological status. Galician Medical Journal, 26 (1), E201913.
EASL-EASD-EASO (2016). Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. Diabetologia, 59 (6), 1121-1140. DOI: 10.1007/s00125-016-3902-y.
Fazel, Y., Koenig, A.B., Sayiner, M., Goodman, Z.D., & Younossi, Z.M. (2016). Epidemiology and natural history of non-alcoholic fatty liver disease. Metabolism, 65 (8), 1017-1025. DOI: 10.1016/j.metabol.2016.01.012.
Shumacher, J.D., & Guo, G.L. (2015). Mechanustic review of drug-induced steatohepatitits Mechanustic review of drug-induced steatohepatitits. Toxicol. Appl. Pharmacol., 289 (1), 40-47. DOI: 10.1016/j.taap.2015.08.022.
Rinella, M.E. (2015). Nonalcoholic fatty liver disease: a systematic review. Jama, 313 (22), 2263-2273. DOI: 10.1001/jama.2015.5370.
Blachier, M., Leleu, H., Peck-Radosavljevic, M., Valla, D.C., & Roudot-Thoraval, F. (2013). The burden of liver disease in Europe: a review of available epidemiological data. J. Hepatol., 58 (3), 593-608. DOI: 10.1016/j.jhep.2012.12.005.
Soresi, M., Noto, D., Cefalu, A.B., Martini, S., Vigna, G.B., Fonda, M., …, & Notarbartolo, A. (2013). Nonalcoholic fatty liver and metabolic syndrome in Italy: results from a multicentric study of the Italian Arteriosclerosis society. Acta Diabetol., 50 (2), 241-249. DOI: 10.1007/s00592-012-0406-1.
Ivashkin, V.T., Drapkina, O.M., Mayev, I.V., Trukhmanov, A.S., Blinov, D.V., Palgova, L.K., ..., & Ushakova, T.I. (2016). Rasprostranennost nealkogolnoy zhirovoy bolezni pecheni u patsiyentov ambulatorno- poliklinicheskoy praktiki v Rossiyskoy Federatsii: rezultaty issledovaniya DIREG 2 [Prevalence of non-alcoholic fatty liver disease in outpatients in the Russian Federation: results from the DIREG 2 study]. Rossiyskiy zhurnal gastroenterelogii, gepatologii, koloproktologii – Russian Journal of Gastroenterology, Hepatology, Coloproctology, 25 (6), 31-41 [in Russian].
Stepanov, Yu.M. (2019). Rezultaty observatsiinoho perekhresnoho doslidzhennia PRELID 2 (2015–2016). Ch. 1. Poshyrenist nealkoholnoi zhyrovoi khvoroby pechinky, kharakterystyka suputnoi patolohii, metabolichnoho syndromu ta yoho okremykh kryteriiv u patsiientiv, yaki zvertaiutsia do terapevtiv i hastroenterolohiv v Ukraini [Results of the observational cross-sectional study PRELID 2 (2015–2016). Part 1. Prevalence of non-alcoholic fatty liver disease, characteristics of concomitant pathology, metabolic syndrome and its individual criteria in patients who turn to therapists and gastroenterologists in Ukraine]. Hastroenterolohiia – Gastroenterology, 53 (1), 26-33 [in Ukrainian].
American College of Obstetricians and Gynecologists (2013). Weight gain during pregnancy. Committee Opinion No. 548. Obstet. Gynecol., 121, 210-212. DOI: 10.1097/01.aog.0000425668.87506.4c.
Grattagliano, I., Ubaldi, E., Napoli, L., Marulli, C.F., Nebiacolombo, C., Cottone, C., & Portincasa, P. (2013). Utility of noninvasive methods for the characterization of nonalcoholic liver steatosis in the family practice. The ‘‘VARES’’ Italian multicenter study. Ann. Hepatol., 12 (1), 70-77.
Younossi, Z.M., Koenig, A.B., Abdelatif, D., Fazel, Y., Henry, L., & Wymer, M. (2016). Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology, 64 (1), 73-84. DOI: 10.1002/hep.28431.
Babak, O.Ya., & Lapshyna, K.A. (2016). Metabolichni zminy ta maloinvazyvna diahnostyka nealkoholnoho steatohepatytu u khvorykh na nealkoholnu zhyrovu khvorobu pechinky na tli hipertonichnoi khvoroby ta ozhyrinnia [Metabolic changes and minimally invasive diagnosis of non-alcoholic steatohepatitis in patients with non-alcoholic fatty liver disease on the background of hypertension and obesity]. Aktualni problemy suchasnoi medytsyny: Visnyk Ukrainskoi medychnoi stomatolohichnoi akademii – Actual problems of modern medicine: Bulletin of the Ukrainian Medical Dental Academy, 16 (4, ch. 2), 57-60 [in Ukrainian].
De Lorenzo, A., Soldati, L., Sarlo, F., & Calvani, M. (2016). New obesity classification criteria as a tool for bariatric surgery indication. World J. Gastroenterol., 22 (2), 681-703. DOI: 10.3748/wjg.v22.i2.681.
Berardis, S., & Sokal, E. (2014). Pediatric non-alcoholic fatty liver disease: an increasingpublic issue. Eur. J. Pediatr., 173 (2), 131-139. DOI: 10.1007/s00431-013-2157-2156.
Korylchuk, N.I., Korylchuk, T.B., Borovyk, I.O., Botsiuk, N.Ye., Riabokon, S.S., Tvorko, V.M., & Mihenko, B.O. (2009). Aspekty korektsiii kompensatornoi hiperinsulinemii ta insulinorezystentnosti u molodykh zhinok z ozhyrinniam [Aspects of correction of compensatory hyperinsulinemia and insulin resistance in young obese women]. Visnyk naukovykh doslidzhen – Bulletin of Scientific Research, 4, 66 [in Ukrainian].
Zvershkhanovskiĭ, F.A., Zhulkevich, I.V., Danilishina, V.S., & Zhulkevich, G.D. (1987). Indicators of lipid metabolism and their relation to disorders of microcirculation in diabetes mellitus. Probl. Endokrinol., 33 (4), 15-18.
Korylchuk, N.I. (2018). Ozhyrinnia yak peredumova metabolichnoho syndromu (ohliad literatury) [Obesity as a precondition for metabolic syndrome (literature review)]. Visnyk naukovykh doslidzhen – Bulletin of Scientific Research, 2, 24-28. DOI: 10.11603/2415-8798.2018.2.9192 [in Ukrainian].
Blazina, I., & Selph, S. (2019). Diabetes drugs for nonalcoholic fatty liver disease: a systematic review. Syst. Rev., 8 (1), 295. DOI: 10.1186/s13643-019-1200-8.
Angulo, P., Bugianesi, E., Bjornsson, E.S., Charatcharoenwitthaya, P., Mills, P.R., Barrera, F., ..., & George, J. (2013). Simple noninvasive systems predict long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology, 145 (4), 782-789.e4. DOI: 10.1053/j.gastro.2013.06.057.
Zhulkevich, I.V., & Vainshtein, S.G. (1986). Algorithm for phenotyping hyperlipoproteinemias and its application to the ‘‘Elektronika BZ-21’’ microcalculator. Laboratornoe delo, 10, 623-625.
Endresen, M.J.R., Morris, J.M., Nobrega, A.C., Buckley, D., Linton, E.A., & Redman, C.W.G. (1998). Serum from preeclamptic women induces vascular cell adhesion molecule-1 expression on human endothelial cells in vitro: A possible role of increased circulating levels of free fatty acids. Am. J. Obstet. Gynecol., 179 (3), 665-670. DOI: 10.1016/s0002-9378(98)70061-4.
Angulo, P., Hui, J.M., Marchesini, G., Bugianesi, E., George, J., Farrell, G.C., …, & Day, C.P. (2007). The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology, 45 (4), 846-854. DOI: 10.1002/hep.21496.
Caballero, F., Fernandez, A., De Lacy, A.M., Fernandez-Checa, J.C., Caballeria, J., & Garcia-Ruiz, C. (2009). Enhanced free cholesterol, SREBP-2 and star expression in human nash. J. Hepatol., 50 (4), 789-796. DOI: 10.1016/j.jhep.2008.12.016.
Savard, C., Tartaglione, E.V., Kuver, R., Haigh, W.G., Farrell, G.C., Subramanian, S., ..., & Ioannou, G.N. (2013). Synergistic interaction of dietary cholesterol and dietary fat in inducing experimental steatohepatitis. Hepatology, 57 (1), 81-92. DOI: 10.1002/hep.25789.
Van Rooyen, D.M., Larter, C.Z., Haigh, W.G., Yeh, M.M., Ioannou, G., …, & Farrell, G.C. (2011). Hepatic free cholesterol accumulates in obese, diabetic mice and causes nonalcoholic steatohepatitis. Gastroenterology, 141 (4), 1393-1403. DOI: 10.1053/j.gastro.2011.06.040.
Wouters, K., van Gorp, P.J., Bieghs, V., Gijbels, M.J., Duimel, H., Lutjohann, D., …, & Hofker, M.H. (2008). Dietary cholesterol, rather than liver steatosis, leads to hepatic inflammation in hyperlipidemic mouse models of nonalcoholic steatohepatitis. Hepatology, 48 (2), 474-486. DOI: 10.1002/hep.22363.
Simonen, P., Kotronen, A., Hallikainen, M., Sevastianova, K., Makkonen, J., Hakkarainen, A., ..., & Yki-Jarvinen, H. (2011). Cholesterol synthesis is increased and absorption decreased in non-alcoholic fatty liver disease independent of obesity. J. Hepatol., 54 (1), 153-159. DOI: 10.1016/j.jhep.2010.05.037.
Walenbergh, S.M., Koek, G.H., Bieghs, V., & Shiri-Sverdlov, R. (2013). Non-alcoholic steatohepatitis: The role of oxidized low-density lipoproteins. J. Hepatol., 58 (4), 801-810. DOI: 10.1016/j.jhep.2012.11.014.
Tomita, K., Teratani, T., Suzuki, T., Shimizu, M., Sato, H., Narimatsu, K., …, & Hibi, T. (2014). Free cholesterol accumulation in hepatic stellate cells: Mechanism of liver fibrosis aggravation in nonalcoholic steatohepatitis in mice. Hepatology, 59 (1), 154-169. DOI: 10.1002/hep.26604.
Chalasani, N., Younossi, Z., Lavine, J.E., Diehl, A.M., Brunt, E.M., Cusi, K., …, & Sanyal, A.J. (2012). The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology, 55 (6), 2005-2023. DOI: 10.1002/hep.25762.
Titov, V.N. (2014). Leptin i adiponektin v patogeneze metabolicheskogo sindroma [Leptin and adiponectin in the pathogenesis of metabolic syndrome]. Klinicheskaya meditsina – Clinical Medicine, 4, 27-38 [in Russian].
Machado, M., Coutinho, J., Carepa, F., Costa, A., Proenca, H., & Cortez-Pinto, H. (2012). How adiponectin, leptin, and ghrelin orchestrate together and correcale with severity of nonalcoholic fatty liver disease. Eur. J. Gastroenterol. Hepatol., 24 (10), 1166-1172. DOI: 10.1097/MEG.0b013e32835609b0.
Chen, S.J., Yen, C.H., Huang, Y.C., Lee, B.J., Hsia, S., & Lin, P.T. (2012). Relationships between inflammation, adiponectin, and oxidative stress in metabolic syndrome. PLoS One, 7 (9), 45693. DOI: 10.1371/journal.pone.0045693.
Ghadge, A.A., Khaire, A.A., & Kuvalekar, A.A. (2018). Adiponectin: a potential therapeutic target for metabolic syndrome. Ctokine Gowth Facto Rev., 39, 151-158. DOI: 10.1016/j.cytogfr.2018.01.004.
Matsuzawa, Y. (2010). Establishment of a concept of visceral fat syndrome and discovery ofadiponectin. Proc. Jpn. Acad. Ser. B. Phys. Biol. Sci., 86 (2), 131-141. DOI: 10.2183/pjab.86.131.
Ahonen, T.M., Saltevo, J.T., Kautiainen, H.J., Kumpusalo, E.A., & Vanhala, M.J. (2012). The association of adiponectin and low-grade inflammation with the course of metabolic syndrome. Nutr. Metab. Cardiovasc. Dis., 22 (3), 285-291. DOI: 10.1016/j.numecd.2010.07.001.
Caimi, G., Hoops, E., Montana, M., & Noto, D. (2012). Evaluation of nitric oxide metabolites in a group of subjects with metabоlic syndrome. Diabetes Metab. Syndr., 6 (3), 132-135. DOI: 10.1016/j.dsx.2012.09.012.
Ang, C., Hillier, C., MacDonald, A., Cameron, A., Greer, I., & Lumsden, M.A. (2001). Insulin-mediated vasorelaxation in pregnancy. BJOG, 108 (10), 1088-1093. DOI: 10.1111/j.1471-0528.2001.00257.x.
Leiva, A., Fuenzalida, B., Barros, E., Sobrevia, B., Salsoso, R., Sáez, T., …, & Sobrevia, L. (2016). Nitric oxide is a central common metabolite in vascular dysfunction associated with diseases of human pregnancy. Curr. Vasc. Pharmacol., 14 (3), 237-259. DOI: 10.2174/1570161114666160222115158.
Sheldon, R.D., Padilla, J., Jenkins, N.T., & Laughlin, M.H. (2015). Chronic NOS inhibition accelerates NAFLD progression in an obese rat model. Am. J. Physiol. Gastrointest Liver Physiol., 15 (308), G540-549. DOI: 10.1152/ajpgi.00247.2014.
Akturk M., Altinova A., Mert I., Dincel A., Sargin A., Buyukkagnici U., …, & Danisman, N. (2010). Asymmetric dimethylarginine concentrations are elevated in women with gestational diabetes. Endocrine, 38 (1), 134-141. DOI: 10.1007/s12020-010-9361-1.
Poniedzialek-Czajkowska, E., Mierzynski, R., Szymula, D., Leszczynska-Gorzelak, B., & Oleszczuk, J. (2016). Intercellular adhesion molecule and endogenous NOS inhibitor: asymmetric dimethylarginine in pregnant women with gestational diabetes mellitus. J. Diabetes Res., 2016, 1342643. DOI: 10.1155/2016/1342643.
Sankaralingam, S., Xu, Y., Sawamura, T., & Davidge, S.T. (2009). Increased lectin-like oxidized low-density lipoprotein receptor-1 expression in the maternal vasculature of women with preeclampsia: role for peroxynitrite. Hypertension, 53 (2), 270-277. DOI: 10.1161/HYPERTENSIONAHA.108.122630.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2021 Actual Problems of Pediatrics, Obstetrics and Gynecology
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish in this journal agree to the following terms:
1. The authors reserve the right to authorship of the work and pass the journal right of first publication of this work is licensed under a Creative Commons Attribution License, which allows others to freely distribute the work published with reference to the authors of the original work and the first publication of this magazine.
2. Authors are entitled to enter into a separate agreement on additional non-exclusive distribution of work in the form in which it was published in the magazine (eg work place in the electronic repository institution or publish monographs in part), provided that the reference to the first publication of this magazine.
3. Policy magazine allows and encourages authors placement on the Internet (eg, in storage facilities or on personal websites) manuscript of how to submit the manuscript to the editor and during his editorial processing, since it contributes to productive scientific discussion and positive impact on the efficiency and dynamics of citing published work (see. The Effect of Open Access).
